– 2nd quarter conference call to be held Tuesday, August 13th, at 8:30 a.m. ET –
Author: Ken Dropiewski
Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results
CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the second quarter and year-to-date of 2024.
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
August 08, 2024 08:00 AM Eastern Daylight Time MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced treatment of the first two patients in the first-in-human feasibility study using its novel Cardiac Surgery […]
SandboxAQ Collaborates with Mayo Clinic on Novel Cardiac Diagnostics
Clinical research study at leading U.S. hospital will further validate the efficacy of advanced, AI-powered magnetocardiography for transformative cardiac diagnostics PALO ALTO, Calif., Aug. 8, 2024 /PRNewswire/ — SandboxAQ today announced a technology collaboration with Mayo Clinic to…
LSU Athletics Becomes First College Sports Program to Use AI-Enabled Digital Stethoscopes From Eko Health to Care for Student-Athletes
Eko Health outfits LSU Athletic Sports Medicine team with CORE 500 digital stethoscopes and AI algorithms for the enhanced detection of cardiac conditions during athlete physical exams BATON ROUGE, La. & SAN FRANCISCO, Aug. 8, 2024 /PRNewswire/ — Eko Health, a pioneer in applying…
Silk Road Medical Reports Second Quarter 2024 Financial Results
SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2024.
CroíValve Announces $16 Million Equity Financing to Fund US Early Feasibility Study of Novel Transcatheter Tricuspid Device
August 07, 2024 08:00 AM Eastern Daylight Time DUBLIN–(BUSINESS WIRE)–CroíValve, a pioneering medical device company focused on the development of a novel transcatheter device for the treatment of tricuspid regurgitation, announced today the closing of $16 million Series B financing. The round, led by the MedTech & Irrus Syndicates, included […]
Centerline Biomedical receives FDA 510(k) clearance for new IOPS® Viewpoint Catheter, further addressing market need to reduce physician exposure to harmful x-ray radiation during image-guided, endovascular procedures
CLEVELAND, Aug. 6, 2024 /PRNewswire/ — Centerline Biomedical, Inc. (“Centerline”), an innovation leader in cardiovascular navigation and visualization systems, announced today that the IOPS Viewpoint Catheter has received US Food and Drug Administration (FDA) 510(k) clearance. The…
Leading Cardiac Diagnostics Innovator Zywie Announces Industry Partnership With MedAxiom
ATLANTA–(BUSINESS WIRE)–Zywie, a cardiovascular diagnostics pioneer specializing in remote cardiac monitoring through wearable biosensor devices and cloud-based data analytic solutions, announced today a partnership with MedAxiom, the cardiovascular community’s premier source for organizational performance solutions. “We are proud to welcome Zywie to the MedAxiom community” Post this “We are proud to welcome Zywie to the […]
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $100 million to the Company, before deducting placement agent fees and other private placement expenses.
Recent
Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change
Route 92 Medical Announces First Commercial Cases in Canada
TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic Stroke
Popular
- No commented posts yet